PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.15%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-30.87%
G&A reduction while AVXL shows 17.76% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.35%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-30.35%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-2.47%
Both companies reducing D&A. Martin Whitman would check industry patterns.
30.79%
EBITDA change of 30.79% while AVXL is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
30.35%
Operating income growth exceeding 1.5x AVXL's 11.33%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-41.49%
Other expenses reduction while AVXL shows 915.39% growth. Joel Greenblatt would examine advantage.
30.26%
Pre-tax income growth 50-75% of AVXL's 45.10%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense growth while AVXL reduces burden. John Neff would investigate differences.
30.26%
Net income growth 50-75% of AVXL's 45.16%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
30.58%
EPS growth 50-75% of AVXL's 47.29%. Martin Whitman would scrutinize operations.
33.88%
Diluted EPS growth 50-75% of AVXL's 49.43%. Martin Whitman would scrutinize operations.
0.94%
Share count reduction exceeding 1.5x AVXL's 5.90%. David Dodd would verify capital allocation.
5.92%
Diluted share reduction below 50% of AVXL's 10.38%. Michael Burry would check for concerns.